Is 3M’s Biggest-Ever Acquisition Worth the Cost?
3M (MMM) recently spent $6.7 billion to acquire Acelity, a medical-tech company with concentrations in specialized surgical applications and wound care.
Healthcare
The latest news in the healthcare sector including biotech and telehealth.
Dow Jones and SPY Trade Lower, Retail Data Disappoints
All of the major indexes and ETFs are trading lower today. The Dow Jones Industrial Average has fallen by 44 points or 0.16% at the time of this writing.Dow Jones Index Falls after Rising for Eight Days
The Dow Jones Industrial Average Index has fallen 0.4% or by 115 points today. The index is trading lower after rising for eight consecutive trading sessions.These Developments Impacted Abbott Laboratories the Most in Fiscal 2017
Abbott Laboratories posted a strong earnings results on January 24, surpassing Wall Street estimates and posting earnings at the high end of its guidance.Why Is Lannett Company Soaring Today?
Generic pharmaceutical player Lannett Company (LCI) entered into a distribution agreement with China-based specialty pharmaceutical firm Sinotherapeutics.Charlotte’s Web Holdings Stock Down after Earnings
Charlotte’s Web Holdings stock (CWBHF)(CWEB) was down 6.6% yesterday after the company reported lower-than-expected Q2 earning results.Walgreens or CVS Stock: Which Is a Better Value Buy?
Walgreens and CVS Health shares are trading at a low valuation multiple. The stocks have fallen 22.3% and 8.7%, respectively, in 2019.Walgreens Will Close 200 US Stores
In a regulatory filing on Tuesday, Walgreens Boots Alliance (WBA) announced that it will close 200 stores in the US to focus on store optimization.Amazon Stock: Does the Recent Slide Indicate a Buy?
Amazon (AMZN) stock has fallen more than 10% since the company reported mixed second-quarter results. The stock fell 3.2% on Monday.Could CVS Health’s Q2 Results Boost Its Stock?
CVS Health (CVS) is set to announce its second-quarter results on August 7. We expect CVS to sustain its momentum in the quarter, supporting its stock.How Analysts View Arrowhead Pharmaceuticals
In Q2, Arrowhead Pharmaceuticals reported revenues of $48.15 million—a YoY rise of 7,305.95%—ahead of the consensus estimate by $5.19 million.Why Is Allakos Soaring Today?
Today, Allakos (ALLK) announced favorable results from its Phase 2 trial evaluating investigational therapy AK002.Kroger Deal Ignited Charlotte’s Web Holdings Last Week
Charlotte’s Web Holdings’ Kroger deal ignited the stock last week. The stock saw an upwards price action of almost 42%. The stock has risen 86% this year.NVS or BMY: Who’s Expected to Post Faster Revenue Growth in 2019?
According to the company’s fourth-quarter earnings conference call, Novartis expects to complete the spin-off of its Alcon business in the second quarter of 2019.FreeStyle Libre Is Multi-Billion Dollar Opportunity for Abbott
In the first quarter, Abbott Laboratories’ (ABT) Diabetes Care franchise reported worldwide sales of $566 million, a YoY rise of 34.4% on a reported basis.Why Pfizer Stock Continues to Tank after Mylan Deal
Pfizer stock (PFE) has fallen 10% in the past two days on its deal with Mylan (MYL) and its lower earnings guidance.How Novartis Is Transforming Its Structure in 2019
Since fiscal 2018, Novartis (NVS) has been focused on transforming itself into a new focused medicines company.How Stryker’s Margins Are Driven by Its CTG Program
Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.Why Did Intec Pharma Crash on Monday?
On Monday, Intec Pharma (NTEC) closed at $0.55—81.61% lower than the previous close. The company failed the pivotal Phase 3 ACCORDANCE trial.What to Expect From Bristol-Myers Squibb in Q2
Bristol-Myers Squibb will release its second-quarter earnings on Thursday. The revenues will likely rise 7.16% YoY to $6.11 billion in the second quarter.A Look at GSK’s Spending and Earnings in Fiscal 2019
In the first-quarter earnings investor presentation, GlaxoSmithKline (GSK) reaffirmed adjusted EPS guidance of a YoY decline of 5%–9% YoY in fiscal 2019.Comparing Pfizer’s and Merck’s Vaccines Businesses
In the first quarter, Pfizer’s (PFE) vaccine franchise reported revenue of $1.61 billion, a YoY (year-over-year) rise of 10.18%.Comparing Pfizer’s and Merck’s 2019 Revenue Growth Trajectories
In its first-quarter earnings investor presentation, Pfizer (PFE) reaffirmed its 2019 revenue guidance of $52.0 billion–$54 billion.What Are Gilead Sciences’ Key Growth Drivers in 2019?
Since the second quarter of 2016, Gilead Sciences has been reporting major YoY revenue declines, mainly due to its lower HCV franchise sales.BHC’s Salix Segment: Xifaxan Drove Its Revenues in Q1
In the first quarter, Bausch Health Companies (BHC) reported revenues of $445 million for its Salix segment.Comparing the Revenue Growth Trajectories of PFE and GSK
On its first-quarter earnings conference call, Pfizer (PFE) maintained its 2019 revenue guidance of $52 billion–$54 billion.Why the US Imposed Sanctions on Iran and Why They Matter
The United States first imposed restrictions on its activities with Iran in 1979, after the seizure of the US embassy in Tehran.A Look at Cosentyx, Novartis’s Fast-Growing Immunology Drug
In the first quarter, Novartis’s (NVS) Cosentyx reported net sales of $791 million, a YoY (year-over-year) rise of 41% on a constant currency basis.ANTM or CI: Comparing Their Revenue Growth in 2019
In its fourth-quarter earnings press release, Anthem (ANTM) guided for 2019 operating revenue of $100 billion, a YoY (year-over-year) rise of $8.7 billion.How Will the Anadarko Acquisition Benefit Chevron?
Chevron (CVX) has agreed to acquire Anadarko (APC) in a cash and equity deal.Optum Is a Major Differentiator for UnitedHealth Group
In fiscal 2018, UnitedHealth Group’s (UNH) health services business, Optum, reported revenues of $101.3 billion, a YoY rise of 11.07%.Analysts Raise Their Target Price for Regeneron in March
Wall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals based on the company’s closing price on March 27.What’s Hurting CVS and Walgreens Stocks?
Walgreens Boots Alliance stock (WBA) fell 6.4% on March 1 after Baird’s reduction in target price.AstraZeneca or Eli Lilly: Which Is Controlling Expenses Better?
In its fourth-quarter earnings press release, AstraZeneca (AZN) guided for a low single-digit YoY (year-over-year) rise in core operating expenses in fiscal 2019.A Look at Spark’s Potential Revenue Contribution to Roche Holdings
Wall Street analysts have projected Spark Therapeutics’ revenues to be $105.64 million, $169.22 million, and $263.76 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.What Are the Key Growth Drivers for GlaxoSmithKline in 2019?
GSK highlighted the prioritization of research and development programs, business development, and new product launches as its key growth drivers in 2018.What Are the Key Growth Drivers for Eli Lilly in Fiscal 2019?
In its fourth-quarter earnings investor presentation, Eli Lilly (LLY) highlighted its newer products such as Emgality, Verzenio, Olumiant, Lartruvo, Taltz, Basaglar, Jardiance, Trulicity, and Cyramza as its key drivers.What Are the Key Growth Drivers for Pfizer in Fiscal 2019?
According to Pfizer’s fourth-quarter earnings conference call, Ibrance has managed to report global revenues of $4.1 billion in fiscal 2018.Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?
In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for revenues of $52 billion to $54 billion for fiscal 2019.AbbVie or Celgene: Which Is Expected to Report Faster EPS Growth?
On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.What Are Abbott Laboratories’ Key Growth Drivers in 2019?
On its fourth-quarter earnings call, Abbott forecast that its Established Pharmaceuticals segment would grow in the mid- to high single digits YoY in the first quarter.Here Are Some Possible Headwinds and Tailwinds for JNJ in 2019
In its fourth-quarter earnings investor presentation, Johnson & Johnson (JNJ) highlighted increasing biosimilar and generic competition, pricing pressure, and the strengthening of the US dollar as key challenges for the company in fiscal 2019.Johnson & Johnson to Focus on Increasing Research and Development
In its fourth-quarter earnings investor presentation, Johnson & Johnson (JNJ) has projected its effective tax rate for fiscal 2019 to fall in the range of 17% to 18%.Pfizer’s Expenses Are Expected to Rise in Fiscal 2019
Pfizer expects its adjusted SI&A expenses to fall by $13.5 billion–$14.5 billion in fiscal 2019—a decline of ~$200 million YoY at the midpoint.Why China’s Iron Ore Demand Could Soon Weaken
As China consumes more than 70% of seaborne-traded iron ore, it’s imperative for iron ore investors to track the country’s demand and outlook.FDA Approves Zimmer Biomet’s ROSA, Stock Up 2.6%
Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.Will Walgreens’s Strategic Initiatives Boost Its Sales?
Walgreens Boots Alliance’s (WBA) sales rose 9.9% to $33.8 billion in the first quarter of fiscal 2019 (which ended on November 30, 2018).What Do Analysts Recommend for Abbott Laboratories in January?
The 12-month consensus analyst recommendation for Abbott Laboratories on January 18 is a “buy.”Can Stanley Black & Decker’s Q4 Earnings Beat the Estimates?
Stanley Black & Decker (SWK) is expected to post an adjusted EPS of $2.1 in the fourth quarter—a decrease of ~4.7% YoY (year-over-year).Teva Pharmaceutical or Mylan: Which Has the Better Debt Profile?
In the first nine months of 2018, Teva Pharmaceutical (TEVA) reduced its net debt level by $3.9 billion to $27.6 billion.
